Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
Director departure
Merger agrmnt [a]
Appointed director
VYNE Therapeutics Inc. (MNLO) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update"
05/11/2023 8-K Quarterly results
Docs: "VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update"
03/09/2023 8-K Quarterly results
Docs: "VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update"
11/10/2022 8-K Quarterly results
08/12/2022 8-K Quarterly results
Docs: "VYNE Therapeutics Reports Second Quarter 2022 Financial Results"
05/12/2022 8-K Quarterly results
03/17/2022 8-K Quarterly results
Docs: "VYNE Therapeutics Reports Year-End 2021 Financial Results and Provides Corporate Update"
11/10/2021 8-K Investor presentation, Quarterly results
Docs: "VYNE Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update",
"INVESTOR PRESENTATION November 2021 Forward Looking Statements This"
08/12/2021 8-K Quarterly results
Docs: "VYNE Therapeutics Reports Second Quarter 2021 Financial Results and Announces New Strategic Direction to Develop Treatments for Immunological and Inflammatory Diseases Company announced license agreement with In4Derm Limited for BETi platform earlier this morning",
"VYNE Therapeutics Announces Licensing of BET Inhibitor Platform for Immuno-Inflammatory Conditions with In4Derm Limited VYNE will have exclusive access to a library of new chemical entities",
"INVESTOR PRESENTATION August 2021 Exhibit 99.3 Forward Looking Statements 2 This"
05/06/2021 8-K Quarterly results
03/04/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "VYNE Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update Conference Call Today at 8:30am Eastern Time"
08/06/2020 8-K Quarterly results
05/11/2020 8-K Quarterly results
Docs: "MENLO THERAPEUTICS INC. CONDENSED CONSOLIDATED BALANCE SHEETS March 31 December 31 2020 2019 A s s e t s CURRENT ASSETS: Cash and cash equivalents $ 57,601 $ 43,759 Restricted cash 855 825 Short-term bank deposits - 12,102 Investment in marketable securities 23,790 16,246 Restricted investment in marketable securities 421 434 Trade receivable 8,333 135 Prepaid and other assets 4,236 1,557 Inventory 3,205 1,356 TOTAL CURRENT ASSETS 98,441 76,414 NON-CURRENT ASSETS: Property and equipment, net 2,834 2,885 Operating lease right-of-use assets 1,721 1,694 In-process research & development 50,300 - Goodwill 4,045 - Prepaid and other assets 3,192 166 TOTAL NON-CURRENT ASSETS 62,092 4,745 TOTAL ASSETS $ 160,533 $ 81,159 MENLO THERAPEUTICS INC. CONDENSED CONSOLIDATED BALANCE SHEETS March 31 Decem..."
03/03/2020 8-K Quarterly results
10/31/2019 8-K Quarterly results
08/01/2019 8-K Quarterly results
Docs: "Menlo Therapeutics Reports Second Quarter 2019 Financial Results and Provides Program Updates Including Accelerated Timeline for Upcoming Clinical Data ~Results from Serlopitant Phase 2 Clinical Trial for the Treatment of Chronic Pruritus of Unknown Origin Anticipated in Q1 2020~"
05/02/2019 8-K Quarterly results
Docs: "Menlo Therapeutics Reports First Quarter 2019 Financial Results"
02/27/2019 8-K Quarterly results
Docs: "Menlo Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results"
03/28/2018 8-K Quarterly results
Docs: "Menlo Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy